Clinical trials: Dalteparin
Acute Ischemic Stroke
PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)
Primary objective: To demonstrate superiority of enoxaparin 40 mg sc qd in the prevention of VTE compared to UFH (unfractionated heparin) 5000 U sc q12 hours given for 10 ± 4 days following acute ischemic stroke.
- Trial name
- NCT00077805
- Testing
- Enoxaparin sodium
- Where
- 15 sites in United States, Australia and 13 more
- Sponsor
- Sanofi
Venous Thromboembolism
Pilot Feasibility and Safety of Administering Weight Adjusted Fixed LMWH Dose
Background Enoxaparin is a commonly used low molecular weight heparin (LMWH) for the treatment of neonatal and children thrombosis that is monitored with anti-factor Xa (anti-Xa) levels.
- Trial name
- FiXET (NCT02486666)
- Testing
- Enoxaparin
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- Hamilton Health Sciences Corporation
Glioma, Malignant
Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to Apixaban
Glioma patients with history of venous thromboembolism (VTE) treated on low molecular weight heparin (LMWH) and who decided with their physician to convert to Apixaban (oral drug) will be enrolled into our study and will collect…
- Trial name
- NCT04895553
- Testing
- Observation of ICH and VTE
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cirrhosis
Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Heparin in Child-Pugh B Cirrhotic Patients
Thrombosis occurring in the small intrahepatic, as well as in the large vessels is involved in the progression of cirrhosis. Anticoagulation could reduce morbidity and mortality in cirrhotic patients
- Trial name
- Childbenox (NCT02271295)
- Testing
- Enoxaparine
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Venous Thromboembolism, Deep Venous Thrombosis
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal…
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Trial name
- MAGNOLIA (NCT05171075)
- Testing
- Abelacimab, Dalteparin
- Where
- 117 sites in United States, Australia and 18 more
- Volunteers
- 417 people
- Sponsor
- Anthos Therapeutics, Inc.
Cancer Patients, Central Venous Catheter Thrombosis
Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) in Cancer Patients
Cancer patients with Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) will be treated with Low Molecular Weight Heparin (LMWH) and apixaban. Study duration is 12 weeks.
- Conditions
- Cancer Patients, Central Venous Catheter Thrombosis, Upper Extremity Thrombosis
- Trial name
- NCT03100071
- Testing
- Apixaban
- Where
- 2 sites in Canada
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Michael Kovacs
Thrombosis, Solid Cancer
Metaxa Hospital THromboprophylaxis Program in Oncological & Surgical Patients
During MeTHOS study will be collected Real World Data the clinical practice regarding Thromboprophylaxis in high thrombotic risk solid tumors patients undergoing surgical and /or chemotherapeutical treatment, for one year…
- Trial name
- MeTHOS (NCT04248348)
- Testing
- Low Molecular Weight Heparin
- Where
- Greece
- Volunteers
- 600 people
- Sponsor
- Metaxa Hospital
LOVASTATIN/TICAGRELOR [VA Drug Interaction]
The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI
The purpose of this study is to determine ticagrelor combining with low molecular weight heparin is effective and safe during PCI or not.
- Trial name
- NCT02658838
- Testing
- Ticagrelor, full amount low molecular weight heparin, half amount low molecular weight heparin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Beijing Anzhen Hospital
Injection Site Bruising, Bruising
Cold Application on the Subcutaneous Injection
The goal of this clinical trial is to compare the effect of cold application at different periods of time on the occurrence of bruising, haematoma and pain in the subcutaneous low molecular weight heparin (LMWH) injected patients.
- Conditions
- Injection Site Bruising, Bruising, Pain
- Trial name
- NCT05771285
- Testing
- Cold application
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Yuksek Ihtisas University
Esophageal Neoplasms
Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer
This is a randomized, single blind, multi-center, phase two clinical trial. Inclusion criteria are consist of non-metastatic esophageal cancer who are going to receive chemo-radiotherapy.
- Trial name
- NCT03254511
- Testing
- Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable, Radiotherapy, Chemotherapeutic Combinations
- Where
- Iran
- Volunteers
- 100 people
- Sponsor
- Mashhad University of Medical Sciences
Diabetic Foot Ulcer
The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)
The primary objective of this 6 month open-label extension trial is to evaluate long-term safety and tolerability of dalteparin in treatment of chronic neuroischaemic foot ulcers in diabetic patients with peripheral arterial…
- Trial name
- NCT00765063
- Testing
- Fragmin
- Where
- 27 sites in Austria, Belgium and 12 more
- Volunteers
- 62 people
- Sponsor
- Pfizer
Neoplasms, Deep Vein Thrombosis
Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients
Study Plan: Adult cancer patients who have a low risk profile and present with DVT will receive dalteparin 200 IU/kg subcutaneously daily (based on actual body weight with a maximum dose of 18,000 IU).
- Trial name
- NCT00041782
- Testing
- Dalteparin (Fragmin)
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Preeclampsia Severe, Toxemia Of Pregnancy
LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention
Preeclampsia is a major cause of maternal and perinatal morbidity and mortality worldwide. Low-dose aspirin started in the first trimester reduces the risk of preeclampsia in high-risk women.
- Conditions
- Preeclampsia Severe, Toxemia Of Pregnancy, Preeclampsia, Pregnancy Complications
- Trial name
- preGO (NCT07361679)
- Testing
- Aspirin, Tinzaparin
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- Alexandra Hospital, Athens, Greece
Malignant Female Reproductive System Neoplasm
Efficacy and Safety of the LovenoxTM (Enoxaparin) Versus HeparinTM Gynecologic Oncology Patients
Prophylactic treatment will start from surgery until the patients are discharged from the hospital(18). Then each patient will have 2 follow up visit in gyne- oncology clinic.
- Trial name
- Lovenox (NCT01356329)
- Testing
- Enoxaparin, Heparin
- Where
- Saudi Arabia
- Volunteers
- 150 people
- Sponsor
- National Guard Health Affairs
Fetal Growth Retardation
Can Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?
The purpose of the study is to investigate if treatment with an anticoagulant drug increases birth weight in pregnancies complicated by fetal growth restriction.
- Trial name
- IUGR (NCT01390051)
- Testing
- Innohep (Tinzaparin), tinzaparin
- Where
- 3 sites in Denmark
- Volunteers
- 50 people
- Sponsor
- University of Aarhus
Gynecologic Neoplasms, Venous Thromboembolism
Thromboprophylaxis After Surgery for Gynecologic Malignancy in China
Venous thromboembolism (VTE) is an important cause of post-operative morbidity and mortality in women undergoing surgery for gynecologic malignancies.
- Conditions
- Gynecologic Neoplasms, Venous Thromboembolism, Low Molecular Weight Heparin, Argatroban
- Trial name
- NCT02935530
- Testing
- s-LMWH, LMWH, Argatroban
- Where
- China
- Volunteers
- 315 people
- Sponsor
- Huazhong University of Science and Technology
Patients Receiving Rivaroxaban Treatment
Validation of Rivaroxaban Assay for US Registration
The objective of the study is to demonstrate the performances of the STA® - Rivaroxaban Calibrator and STA® - Rivaroxaban Control in combination with the STA® - Liquid Anti-Xa to determine the quantity of rivaroxaban in plasma…
- Trial name
- NCT02333929
- Testing
- STA- Rivaroxaban Calibrator&Control
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Diagnostica Stago
Direct Oral Anticoagulants (DOACs), Femoral Fractures
Impact of Treatment With Oral Anticoagulants of Patients With Fractures of the Upper End of the Femur
In 2023, oral anticoagulant treatments (anti Xa: apixaban , rivaroxaban, etc.) are tending to replace anti vitamin K treatments in many medical indications. Their prescription is increasing rapidly in the elderly.
- Conditions
- Direct Oral Anticoagulants (DOACs), Femoral Fractures, Surgery
- Trial name
- ANTI_XA AOD (NCT06382584)
- Testing
- Femoral fracture surgery
- Where
- France
- Volunteers
- 610 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Thromboembolism, Postpartum DVT
Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery
The aim of this study is to evaluate the efficacy of two dosing regimens of low molecular weight heparin (LMWH) to reach prophylactic anti-factor Xa levels in post-cesarean delivery women.
- Conditions
- Thromboembolism, Postpartum DVT, Thrombosis
- Trial name
- NCT04305756
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- University of Utah
Morbid Obesity, Obesity
Fondaparinux Population Pharmacokinetic to Morbid Obese Patients in Post-operatory Bariatric Surgery
After bariatric surgery , thromboembolics complications are major cause of mortality. However, in obese patients, thromboprophylaxia is a controversy.
- Conditions
- Morbid Obesity, Obesity, Surgery
- Trial name
- NCT01064596
- Testing
- blood samples
- Where
- 3 sites in France
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne